Table 1.
Summary of Study and Patient Characteristics, Organized According to the Type of Analysis They Were Incorporated Under (i.e., Aggregate Data or Individual Patient Data Meta-Analysis)
| Study Characteristics | Aggregate Data |
Individual Patient Data |
||
|---|---|---|---|---|
| Publications Included |
Sample Size |
Publications Included |
Sample Size |
|
| n = 28 | n = 7011 | n = 24 | n = 6274 | |
| Study type, n (%) | ||||
| Prospective cohort | 1 (4) | 27 (0) | 1 (4) | 27 (0) |
| Prospective trial | 6 (21) | 292 (4) | 6 (25) | 292 (5) |
| RCTs | 1 (4) | 492 (7) | 1 (4) | 492 (8) |
| Retro cohort | 20 (71) | 6200 (88) | 16 (67) | 5463 (87) |
| Geographic region, n (%) | ||||
| Asia-Pacific | 12 (43) | 1659 (24) | 10 (42) | 1099 (18) |
| Europe | 7 (25) | 1126 (16) | 5 (21) | 949 (15) |
| Middle East | 1 (4) | 124 (2) | 1 (4) | 124 (2) |
| North America | 8 (29) | 4102 (59) | 8 (33) | 4102 (65) |
| Publication date, median (range) | 2014 (2000–2021) | 2016 (2000–2021) | ||
| Follow-up time (mo), median (range) | 42 (18–97) | 42.2 (18–97) | ||
| Median age (ys), median (range) | 59 (55–67) | 59 (55–67) | ||
| Proportion of stage 3 patients, median (range) | 100% (0%–100%) | 100% (0%–100%) | ||
| pCR rate, median (range) | 17% (4%–38%) | 19% (4%–38%) | ||
| pCR definition, n (%) | ||||
| T0N0 | 15 (54) | 4504 (64) | 13 (54) | 4173 (67) |
| T0 | 6 (21) | 1540 (22) | 5 (21) | 1185 (19) |
| Not defined | 7 (25) | 967 (14) | 6 (25) | 916 (15) |
| AJCC edition | ||||
| Fifth | 2 (7) | 212 (3) | 2 (8) | 212 (3) |
| Sixth | 6 (21) | 2887 (41) | 6 (25) | 2887 (46) |
| Seventh | 9 (32) | 2769 (39) | 7 (29) | 2438 (39) |
| Eight | 1 (4) | 92 (1) | 1 (4) | 92 (1) |
| Not reported | 10 (36) | 1051 (15) | 8 (33) | 645 (10) |
| Evaluated association between pCR and OS, n (%) | 27 (96) | 6979 (100) | 23 (96) | 6292 (100) |
| Evaluated association between pCR and EFS, n (%) | 9 (32) | 1649 (24) | 7 (29) | 1530 (24) |
| Recurrence definition, n (%) | ||||
| RFS | 4 (14) | 834 (12) | 4 (17) | 834 (13) |
| PFS | 5 (18) | 595 (8) | 3 (12) | 189 (3) |
| RFS/PFS | 1 (4) | 32 (0) | 1 (4) | 32 (1) |
| DFS | 2 (7) | 584 (8) | 2 (8) | 584 (9) |
| DFS/DSS | 1 (4) | 122 (2) | 1 (4) | 122 (2) |
| Distant recurrence | 1 (4) | 85 (1) | 1 (4) | 85 (1) |
| TTP | 1 (4) | 157 (2) | 1 (4) | 157 (3) |
| Not included | 13 (46) | 4602 (66) | 11 (46) | 4271 (68) |
| EFS start date, n (%) | ||||
| Diagnosis | 2 (7) | 1868 (27) | 2 (8) | 1868 (30) |
| First treatment | 8 (29) | 1373 (20) | 7 (29) | 1018 (16) |
| Enrollment | 1 (4) | 48 (1) | 1 (4) | 48 (1) |
| Surgery | 11 (39) | 1724 (25) | 9 (38) | 1547 (25) |
| Not defined | 6 (21) | 1998 (28) | 5 (21) | 1793 (29) |
| Reported adjuvant therapy use, n (%) | ||||
| Yes | 9 (32) | 2763 (39) | 6 (25) | 2077 (33) |
| No | 19 (68) | 4248 (61) | 18 (75) | 4197 (67) |
| % patients who received adjuvant treatment | 83.1% (13.7%–100%) | 65.5% (13.7%–100%) | ||
| Preop cycles, n (%) | ||||
| ≤2 | 12 (43) | 1409 (20) | 11 (46) | 1204 (19) |
| ≥3 | 8 (29) | 1321 (19) | 6 (25) | 1144 (18) |
| Not reported | 8 (29) | 4281 (61) | 7 (29) | 3926 (63) |
| XRT dose, n (%) | ||||
| <50 Gy | 12 (43) | 1914 (27) | 11 (46) | 1559 (25) |
| ≥50 Gy | 10 (36) | 2878 (41) | 8 (33) | 2622 (42) |
| Not reported | 6 (21) | 2219 (32) | 5 (21) | 2093 (33) |
Note: The relative proportions of both the number of studies and patient sample size for each variable were included.
AJCC, American Joint Committee on Cancer; CI, confidence interval; DFS, disease-free survival; DSS, disease-specific survival; EFS, event-free survival; HR, hazard ratio; Op, operative; OS, overall survival; pCR, pathologic complete response; PFS, progression-free survival; RCT, randomized controlled trial; Retro, retrospective; RFS, recurrence-free survival; TTP, time to progression; XRT, radiotherapy.